X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    New Delivery Path Brings To Light Efficacy of Immunotherapy

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    New Delivery Path Brings To Light Efficacy of Immunotherapy

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Europe

GSK adds to its commitment to GAVI Alliance to help protect millions more children against infectious diseases

Yuvraj_pawp by Yuvraj_pawp
31st July 2013
in Europe, News

GlaxoSmithKline (GSK) has increased its commitment to the GAVI Alliance to provide vaccines to developing countries, helping to protect millions more children against infectious diseases.

Under this new agreement, GSK will provide an additional 240 million doses of Synflorix™ to developing countries over the next ten years, helping protect up to 80 million more children from pneumococcal diseases such as meningitis and pneumonia.

This builds on the 480 million doses of the vaccine that GSK has already committed to GAVI through the Advance Market Commitment (AMC) framework, which is designed to bring heavily discounted vaccines to children living in the world’s poorest countries.

GSK provides GAVI with a broad portfolio of vaccines including: Synflorix which protects against pneumococcal disease; Rotarix™ vaccination for rotavirus, a common cause of diarrhoea; Cervarix® which helps protect girls against cervical cancer caused by human papilloma virus; and a combined vaccination for diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b.

With this new vaccine supply agreement extension, GSK is committed to provide more than 850 million vaccine doses that will help protect up to 300 million children and adolescent girls in the developing world from these diseases by 2024.

Christophe Weber, President and General Manager of Vaccines, GSK said: “Since its creation, GAVI and its support for the Advance Market Commitment has made a tremendous impact, saving millions of children’s lives. Pneumococcal disease however continues to cause death and suffering in our world’s poorest countries. We are proud to extend our commitment to GAVI to help save millions more children from this deadly disease.”

GSK has committed to provide the additional 240 million doses of Synflorix to GAVI at $3.40 per dose, a small fraction of developed world prices.

To date, more than 50 million doses of the vaccine have been delivered to GAVI countries, including Uganda, Mozambique, Madagascar, Kenya, Ethiopia and Pakistan. Zambia is the most recent country to include the vaccine in its national immunisation programme under the AMC in July 2013.

Tags: Europe
Previous Post

Researchers target HER1 receptor for peptide cancer vaccine, therapeutic agents

Next Post

Scientists discover potential new way to treat anxiety

Related Posts

Drug Development

New Delivery Path Brings To Light Efficacy of Immunotherapy

1st April 2023
Quotient Sciences completes integration of drug substance into Translational Pharmaceutics Platform
Facilities & Operation

ÂŁ277m Funding Set To Benefit UK Life Sciences Manufacturing

31st March 2023
Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Next Post

Scientists discover potential new way to treat anxiety

Latest News

Drug Development

New Delivery Path Brings To Light Efficacy of Immunotherapy

1st April 2023
Cathay Cargo signs global airline partnership with Tower Cold Chain
Packaging & Logistic

Cathay Cargo signs global airline partnership with Tower Cold Chain

31st March 2023
Quotient Sciences completes integration of drug substance into Translational Pharmaceutics Platform
Facilities & Operation

ÂŁ277m Funding Set To Benefit UK Life Sciences Manufacturing

31st March 2023
Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In